Clinical Trials Browser

Phase 2/3 × NETWORK × Thoracic × Clear all

NCT04093167 2026-03-11

Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

Phase 2/3 Recruiting

Lung Neoplasms

NCT03851445 2025-12-05

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Phase 2/3 Recruiting

10,000 enrolled

Previously Treated Non-Small Cell Lung Cancer

NCT05096663 2025-05-15

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02784171 2024-12-10

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Phase 2/3 Completed

520 enrolled 16 charts 1 FDA

Other solid neoplasmThoracic

Mesothelioma

NCT00245154 2023-08-04

Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2/3 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00006229 2020-04-06

Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer

Phase 2/3 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01208064 2018-07-12

Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy

Phase 2/3 Terminated

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms